U.S. markets close in 4 hours 58 minutes
  • S&P 500

    +0.31 (+0.01%)
  • Dow 30

    -9.86 (-0.03%)
  • Nasdaq

    -10.93 (-0.10%)
  • Russell 2000

    +13.89 (+0.76%)
  • Crude Oil

    +1.59 (+2.06%)
  • Gold

    +14.40 (+0.82%)
  • Silver

    +0.43 (+2.06%)

    +0.0013 (+0.12%)
  • 10-Yr Bond

    +0.0240 (+0.65%)

    +0.0034 (+0.29%)

    -0.5620 (-0.40%)

    +239.47 (+1.48%)
  • CMC Crypto 200

    -1.23 (-0.32%)
  • FTSE 100

    +60.68 (+0.81%)
  • Nikkei 225

    -134.99 (-0.48%)

One C4 Therapeutics, Inc. (NASDAQ:CCCC) insider upped their stake in the previous year

Viewing insider transactions for C4 Therapeutics, Inc.'s (NASDAQ:CCCC ) over the last year, we see that insiders were net buyers. This means that a larger number of shares were purchased by insiders in relation to shares sold.

While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.

See our latest analysis for C4 Therapeutics

C4 Therapeutics Insider Transactions Over The Last Year

The CEO, President & Director Andrew Hirsch made the biggest insider purchase in the last 12 months. That single transaction was for US$84k worth of shares at a price of US$8.40 each. That means that an insider was happy to buy shares at around the current price of US$8.77. That means they have been optimistic about the company in the past, though they may have changed their mind. If someone buys shares at well below current prices, it's a good sign on balance, but keep in mind they may no longer see value. The good news for C4 Therapeutics share holders is that an insider was buying at near the current price. Andrew Hirsch was the only individual insider to buy during the last year.

You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!


There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).

Insider Ownership Of C4 Therapeutics

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. We usually like to see fairly high levels of insider ownership. It appears that C4 Therapeutics insiders own 8.3% of the company, worth about US$36m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

So What Do The C4 Therapeutics Insider Transactions Indicate?

The fact that there have been no C4 Therapeutics insider transactions recently certainly doesn't bother us. But insiders have shown more of an appetite for the stock, over the last year. Overall we don't see anything to make us think C4 Therapeutics insiders are doubting the company, and they do own shares. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. For example, C4 Therapeutics has 3 warning signs (and 1 which makes us a bit uncomfortable) we think you should know about.

Of course C4 Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here